Flupentixol
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
Flupentixol: An Emerging Candidate for Retinal Dystrophy with Extraocular Anomalies
One-Sentence Summary
Flupentixol’s original licensed indication is not recorded in this evidence pack (data gap). The TxGNN model predicts a possible association with retinal dystrophy with or without extraocular anomalies, but this is currently supported by 0 clinical trials and 15 publications, none of which specifically link flupentixol to this condition. The drug’s own mechanistic rationale states no known pharmacological connection to this — or to any of the eight other — predicted indications.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in evidence pack |
| Predicted New Indication | Retinal dystrophy with or without extraocular anomalies |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L5 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack (original MOA and original indications are both recorded as data gaps).
The evidence pack’s own repurposing rationale, however, does identify flupentixol pharmacologically as a dopamine D1/D2 receptor antagonist. Based on that, no known or plausible mechanistic link to retinal dystrophy with extraocular anomalies has been identified — this is a congenital, monogenic developmental disorder, and its pathophysiology does not intersect with dopaminergic receptor blockade.
The same pattern holds across all nine TxGNN-predicted indications for this drug (see table below): each is a rare congenital or genetic disorder (e.g. Charcot-Marie-Tooth type 1G, a congenital disorder of glycosylation, polymicrogyria, hydranencephaly, X-linked myopias, atypical glycine encephalopathy) with no dopaminergic mechanistic rationale, no clinical trial evidence, and — for eight of the nine — no literature evidence at all. This pattern is consistent with a high-score artefact on sparsely-connected (“orphan”) disease nodes in the knowledge graph, rather than a biologically grounded repurposing signal.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
The evidence pack returned 15 publications for this disease term; the top 10 are listed below. None of these mention flupentixol — they were retrieved via a disease-only literature search and describe general ophthalmic/orbital pathology, not a drug–disease relationship. They are listed for transparency but do not constitute supporting evidence for this repurposing candidate.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 9416661 | 1997 | Review | Seminars in Ultrasound, CT, and MR | Overview of orbital infections secondary to sinusitis; not drug-related |
| 20127583 | 2010 | Review | Seminars in Neurology | Clinical approach to diplopia; not drug-related |
| 22241537 | 2012 | Review | Klinische Monatsblätter für Augenheilkunde | Overview of congenital ptosis; not drug-related |
| 38249493 | 2023 | Review | Taiwan Journal of Ophthalmology | Congenital anomalies of lens shape; not drug-related |
| 7035111 | 1981 | Review | Documenta Ophthalmologica | Wagner-Stickler syndrome complex (vitreoretinal degeneration); not drug-related |
| 38321238 | 2024 | Review | Pediatric Radiology | Imaging features of pediatric ocular pathologies; not drug-related |
| 109006 | 1979 | Case Report | American Journal of Ophthalmology | Case series of unilateral cryptophthalmia; not drug-related |
| 24413161 | 2014 | Case Report | Journal of Neuro-Ophthalmology | Case of congenital trochlear-oculomotor synkinesis; not drug-related |
| 19826317 | 2009 | Case Report | Optometry and Vision Science | Case of congenital extraocular muscle fibrosis; not drug-related |
| 19064847 | 2008 | Case Report | Archives of Ophthalmology | Case series of orbital arteriovenous malformations; not drug-related |
UK Market Information
Flupentixol is currently not marketed in the UK dataset covered by this evidence pack, and no marketing authorisations are on record (0 licences).
Other TxGNN-Predicted Indications (Ranks 2–9)
For transparency, this candidate profile (“TW-DB00875-multi”) includes nine TxGNN-predicted indications in total. All show the same pattern: very high TxGNN scores, L5 evidence level, and a “Hold” recommendation, with the model’s own rationale stating no mechanistic plausibility.
| Rank | Predicted Indication | TxGNN Score | Trials | Literature | Recommendation |
|---|---|---|---|---|---|
| 2 | Charcot-Marie-Tooth disease, demyelinating, type 1G | 99.99% | 0 | 0 | Hold |
| 3 | Congenital disorder of glycosylation with defective fucosylation | 99.99% | 0 | 0 | Hold |
| 4 | Polymicrogyria, perisylvian, with cerebellar hypoplasia and arthrogryposis | 99.99% | 0 | 0 | Hold |
| 5 | Hydranencephaly (disease) | 99.99% | 0 | 0 | Hold |
| 6 | Myopia, X-linked | 99.99% | 0 | 0 | Hold |
| 7 | Syndromic myopia | 99.99% | 0 | 0 | Hold |
| 8 | Myopia 26, X-linked, female-limited | 99.98% | 0 | 0 | Hold |
| 9 | Atypical glycine encephalopathy | 99.98% | 0 | 0 | Hold |
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Note: TFDA/MHRA labelling data (warnings, contraindications, DDI) is recorded as a blocking data gap (DG001) in this evidence pack and has not been reviewed.
Conclusion and Next Steps
Decision: Hold
Rationale: Every predicted indication in this profile is at Evidence Level L5 (model prediction only), with no clinical trials and, in eight of nine cases, no literature at all. The one candidate with literature (rank 1) has publications that do not mention flupentixol and are not linked to it mechanistically. The evidence pack’s own rationale explicitly states there is no known pharmacological link between flupentixol’s dopamine D1/D2 antagonism and any of these congenital/genetic disorders. This pattern is consistent with a knowledge-graph artefact on sparsely-connected disease nodes rather than a genuine repurposing signal.
To proceed, the following is needed:
- Original indication and mechanism of action data for flupentixol (currently a data gap, DG002)
- TFDA/MHRA labelling data — warnings and contraindications — to enable a basic safety screen (blocking gap, DG001)
- A drug-specific (not disease-only) literature and clinical evidence search for each predicted indication
- An independent pharmacological/genetic plausibility review, given that all nine predicted indications are monogenic congenital disorders with no established dopaminergic aetiology
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.